MARRONE BIO INNOVATIONS, INC.

(MBII)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Marrone Bio Innovations Acquires New Bacteria Strains for Second-Generation Bioherbicide

12/16/2021 | 10:24am EDT


ę MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
MARRONE BIO INNOVATIONS, INC. -1.85% 1.06 Delayed Quote.49.96%
NOVOZYMES A/S -1.04% 437.6 Delayed Quote.-17.68%
All news about MARRONE BIO INNOVATIONS, INC.
05/13MARRONE BIO INNOVATIONS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
05/11TRANSCRIPT : Marrone Bio Innovations, Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (MBII) MARRONE BIO INNOVATIONS Posts Q1 Revenue $11.1M, vs. Street Est o..
MT
05/11Marrone Bio Innovations, Inc. Reports Earnings Results for the First Quarter Ended Marc..
CI
05/11Earnings Flash (MBII) MARRONE BIO INNOVATIONS Posts Q1 Loss $-0.04, vs. Street Est of $..
MT
05/11Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results
GL
05/11Marrone Bio Innovations, Inc. Provides Revenue Guidance for the First Half of 2022
CI
05/04MARRONE BIO INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Marrone Bi..
BU
04/27MARRONE BIO INVESTOR ALERT BY THE FO : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
04/27MARRONE BIO INNOVATIONS TO REPORT FI : 30 p.m. Eastern Time
AQ
More news
Analyst Recommendations on MARRONE BIO INNOVATIONS, INC.
More recommendations
Financials (USD)
Sales 2022 56,5 M - -
Net income 2022 -10,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,07x
Yield 2022 -
Capitalization 193 M 193 M -
Capi. / Sales 2022 3,42x
Capi. / Sales 2023 2,72x
Nbr of Employees 153
Free-Float 98,0%
Chart MARRONE BIO INNOVATIONS, INC.
Duration : Period :
Marrone Bio Innovations, Inc. Technical Analysis Chart | MBII | US57165B1061 | MarketScreener
Technical analysis trends MARRONE BIO INNOVATIONS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,06 $
Average target price 1,38 $
Spread / Average Target 29,7%
EPS Revisions
Managers and Directors
Kevin R. Helash Chief Executive Officer & Director
LaDon Johnson Chief Financial Officer
Robert A. Woods Chairman
Amit Vasavada Chief Technology Officer, Senior VP-R&D
Zachary S. Wochok Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MARRONE BIO INNOVATIONS, INC.49.96%197
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.78.15%25 662
ICL GROUP LTD32.92%15 751
PJSC PHOSAGRO35.97%15 510
UPL LIMITED9.99%7 929
YUNNAN YUNTIANHUA CO., LTD.32.67%7 341